Growth and Development Study of Alglucosidase Alfa
A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa
Sponsor: Genzyme, a Sanofi Company
A PHASE4 clinical study on Acid Maltase Deficiency Disease and Glycogen Storage Disease Type II (GSD-II), this trial is completed. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2022 — Sep 2022 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE4
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Mar 2020 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genzyme, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .